Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elraglusib - Actuate Therapeutics

Drug Profile

Elraglusib - Actuate Therapeutics

Alternative Names: 9 ING 41

Latest Information Update: 23 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northwestern University; University of Illinois at Chicago
  • Developer Actuate Therapeutics; Incyte Corporation; Levine Cancer Institute; University of Kansas Medical Center
  • Class Antineoplastics; Benzofurans; Dioxolanes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Pancreatic cancer; Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenoid cystic carcinoma; Myelofibrosis; Neuroblastoma; Pancreatic cancer; Salivary gland cancer
  • Phase I/II Cancer
  • Preclinical Brain cancer; Chronic lymphocytic leukaemia; Colorectal cancer

Most Recent Events

  • 18 Jan 2024 Actuate Therapeutics completes a phase II clinical trials in Myelofibrosis (Monotherapy, Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT04218071)
  • 01 Aug 2023 Elraglusib - Actuate Therapeutics receives Orphan Drug status for Pancreatic cancer (Combination therapy, Late-stage disease) in USA
  • 20 Jun 2023 Phase-I/II clinical trials in Cancer (Second-line therapy or greater, Refractory metastatic disease, Combination therapy) in France (IV) (NCT03678883)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top